Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer

MONDAY, March 13, 2023 -- For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news